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Abstract  
Recent work has highlighted a number of compounds that target bacterial virulence by 
affecting gene regulation.  In this work, we show that small-molecule inhibitors affect the 
expression of the type III secretion system (T3SS) of Escherichia coli O157:H7 in liquid 
culture and when the bacteria are attached to bovine epithelial cells.  The inhibition of 
T3SS expression resulted in a reduction in the capacity of the bacteria to form attaching 
and effacing lesions.  Our results show a marked variation in the ability of four 
structurally-related compounds to inhibit the T3SS of a panel of isolates. Using 
transcriptomics, we provide a comprehensive analysis of the conserved- and inhibitor-
specific transcriptional responses to the four compounds.  These analyses of gene 
expression show that numerous virulence genes, located on horizontally-acquired DNA 
elements, are affected by the compounds but the number of genes significantly affected 
varied markedly between the compounds.  Overall, we highlight the importance of 
assessing the effect of such “anti-virulence” agents on a range of isolates and discuss the 
possible mechanisms which may lead to the co-ordinate down-regulation of horizontally 
acquired virulence genes.   
2 
Introduction  
Outbreaks of Enterohaemorrhagic E. coli (EHEC) infection occur sporadically in both the 
developed and developing world causing diarrhoeal disease that can progress to 
haemorrhagic colitis and haemolytic uremic syndrome (HUS) (22).  E. coli O157:H7 is 
the dominant serotype in North America, parts of Europe and Japan, and its pathogenicity 
has been studied extensively at the molecular level.  A number of key virulence factors 
are known to be required for disease progression including the Shiga toxins and the type 
III secretion system (T3SS) required for characteristic attaching and effacing (A/E) lesion 
formation (13).   The T3SS is encoded on the locus of enterocyte effacement (LEE) 
pathogenicity island containing 41 genes on 5 main operons (18).  Deletion of the LEE4 
operon prevents A/E lesion formation and prevents colonisation of the terminal rectum, 
the principle colonisation site in cattle (24).  To this extent, vaccines that target EHEC 
T3SS are being developed for application in cattle (28).  Furthermore, given the central 
role of the T3SS for bovine colonization, it is highly likely that inhibition of a functional 
T3SS could prevent colonisation of humans, thereby limiting disease.   
As the prevalence of antibiotic resistant strains increases, targeting virulence 
determinants of pathogenic bacteria has become an increasingly attractive alternative to 
bactericidal antibiotics.  The major advantage of these compounds is significantly less 
positive selection on resistant mutants as the non-pathogenic normal flora are unaffected 
by treatment (14).  Such a class of ‘virulence blockers’ has been described that inhibit 
T3SS in Yersinia spp. and have been shown to be broadly effective in a number of 
pathogenic bacteria that utilise T3SS including Chlamydia spp., Salmonella enterica 
serovar Typhimurium, and Enteropathogenic E. coli (EPEC).  The mechanism of 
inhibition in each is incompletely understood. However, it is clear that transcription of 
T3S genes in these pathogens is reduced.  Whether this is due to feedback from the T3S 
machinery or by direct effects on transcription factors remains to be determined.  
Treatment of bacteria with μM concentrations of inhibitors is sufficient to reduce S. 
Typhimurium invasion of cultured epithelial cells and induction of enteritis in vivo (11), 
arrest maturation of Chlamydia sp. inclusions (37), and reduce proliferation of Yersinia 
pseudotuberculosis (25).  Further experiments have shown that the antichlamydial 
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activity of this family can be reversed by the addition of iron suggesting that the activity 
of these compounds may be linked to iron availability in the cell, although the 
mechanisms behind this reversal are unknown.  In Vibrio cholera a ‘virulence blocker’ 
has been described that reduces expression of cholera toxin (CT) and the toxin co-
regulated pilus (TCP).  This inhibitor has been shown to act by post-translationally 
inactivating the AraC family regulator, ToxT, suggesting regulators of virulence genes 
may be an important target for this class of inhibitors (36).  A recent study has also 
shown that a structurally distinct compound, LED209, can prevent the phosphorylation of 
the E. coli O157 QseC membrane protein, a sensor of host adrenergic molecules (30).  
This inhibition of QseC function leads to impaired expression of virulence factors and 
affects colonization of tissue culture cells by downregulation of Ler, the master regulator 
of the T3SS of E. coli O157 (30). Of particular importance to this study is a previous 
report that described the screening of virulence blockers in EPEC (9).  This previous 
study showed that the addition of the compound, with structural similarity to the ones 
described in this work, transcriptionally down-regulated the major operons of the EPEC 
LEE.  However, the extent to which other genes were affected was not examined.  Here 
we characterize the effects of four structurally-related salicylidene acylhydrazide 
virulence blockers on global gene expression in E. coli O157:H7.  These analyses show 
that transcriptional repression of the T3SS is also accompanied by repression of virulence 
genes encoded on mobile genetic elements demonstrating global effects on virulence 
gene regulation.  We also show that these inhibitors effectively reduce formation of actin 
pedestals in vitro.   
MATERIALS AND METHODS  
Bacterial strains and plasmids 
Unless otherwise stated, all experiments were performed using E. coli O157:H7 strain 
TUV-930, a Shiga-toxin negative derivative of strain EDL933 (3).  To examine the effect 
of the inhibitors across a range of strains and phage-types (PTs) six additional E. coli 
O157 strains were used: ZAP 3 (PT 2), ZAP 11 (PT 21/28), ZAP 12 (PT 21/28), ZAP 
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229, (PT 2), ZAP 231 (PT 4) and ZAP 243 (PT 8).  The green fluorescent protein (GFP) 
reporter plasmids pAJR71-75 used in this study have been described previously (32, 34).  
Inhibitors and media 
The compounds (ME0052-0055; Figure 1), selected on the basis of their ability to inhibit 
the T3SS of related pathogens (25) (2) (37), were prepared and supplied by Mikael 
Elofsson.  The compounds have been previously reported using a number of different 
nomenclatures: ME0052 (INP0010 & compound 8), ME0053 (INP0403 & compound 
11), ME0054 (INP0401 & compound 10) and ME0055 (INP0031 & compound 17) (25).  
Stock solutions were prepared in DMSO, aliquotted and stored at -20oC in the dark.  The 
final DMSO concentration added to the bacteria was kept below 2% in all experiments.  
Minimal essential media with HEPES modification (MEM-HEPES, Sigma M7278) was 
used in this study to promote expression of the LEE pathogenicity island.  This was 
supplemented with 250 nM Fe(NO3)2 and glucose to give a final concentration of 0.2 %.  
Antibiotics were included when required at the following concentrations: 12.5 µg.ml–1 
chloramphenicol and 25 µg.ml–1 kanamycin.  To examine the effects of higher 
concentrations of iron supplementation on the effects of the inhibitors, 200 μM FeSO4 
was added to the growth medium when stated. 
Protein secretion and Western Blot analyses 
Bacteria were cultured overnight in LB and diluted to an OD600 ≤ 0.05 in prewarmed 
MEM-HEPES medium, supplemented with 250 nM Fe(NO3)2 and glucose to give a final 
concentration of 0.2 %.  When required, the specific growth rate was reduced by addition 
of 0.1M or 0.2M NaCl to this media.  Cultures were grown at 37 °C to an OD600 of 0.8 
and then secreted proteins were extracted by TCA precipitation as described previously 
(35).  For protein-localization experiments, whole-cell fractions were prepared by 
centrifugation (20 min, 4000 x g), washed twice in 20 ml PBS, sonicated and resuspended 
in 400 µl protein A buffer (35).  Proteins were analyzed by SDS-PAGE, and Western 
blotting for Tir, EspD and GroEL was carried out as described previously (35).  The 
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Western blots were quantified using Scion image software allowing comparisons between 
different samples.   
Transcriptomics 
Transcriptional profiling of cultures treated with the inhibitors was carried out essentially 
as described previously (33).  In brief, overnight cultures of E. coli TUV-930 grown in 
MEM-HEPES (Sigma) supplemented with 250 nM Fe(NO3)2 and glucose to a final 
concentration of 0.2% and then diluted to an OD600 of 0.1 in the same media.  Inhibitor 
was added to test cultures at a final concentration of 20 μM and an equal volume of 
DMSO added to reference cultures.  At an OD600 of 0.8, 15 ml cultures were stabilized 
in an equal volume of RNAprotect (Qiagen) and RNA extracted using a Qiagen RNeasy 
Mini kit.  DNA contamination was removed by DNaseI treatment (Ambion).  Total RNA 
was assessed for quality and quantified using an Aglient 2100 Bioanalyser.  Synthesis of 
cDNA and labeling of total RNA was performed using an Amersham CyScribe Post-
Labelling Kit as per manufactures instructions.  The cDNA was hybridized to 70mer 
spotted oligonucleotide arrays containing ORFs from E. coli K-12, E. coli Sakai VT2, 
and E. coli EDL933 (University of Birmingham, UK) using a Genomic Solutions 
GeneTac hybridization machine.  Hybridized slides were scanned using a Genepix 4000A 
scanner and GenePix 7.0 software (Axon Instruments, Union City, Calif.).  Data were 
analyzed using Genespring GX 7.3.1 (Agilent).  The MIAME compliant data are 
deposited on the Gene Expression Omnibus (GEO) at NBCI under the GEO accession 
number (GSE10319).  
Regulon analysis for global regulators 
In order to determine if post-translational modification of regulators was contributing to 
regulation by ME0052-55, the regulons for H-NS, LexA, FUR and PchA were defined 
from the literature and analysed in Genespring 7.3.1. The H-NS, LexA and FUR regulons 
have not been elucidated for E. coli O157 but have been described for K-12 and provides 
an indicator of activity within the E. coli common backbone. The H-NS regulon has 
previously been described by Oshima et al (26) and the LexA regulon has been described 
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for K-12 using transcriptomics and chromatin-immunoprecipitation (ChIP) studies (40) . 
For both of these regulons, K-12 gene designations were converted to O157 “z” numbers 
using Genespring 7.3.1 and by BLAST analysis. The FUR regulon has been described by 
Gamma-Castro et al (8) and was acquired from RegulonDB 
(http://regulondb.ccg.unam.mx/) and similarly converted to “z” numbers using 
Genespring 7.3.1 and BLAST. The PchA and Ler regulons were recently defined by 
transcriptomics and ChIP studies for E. coli O157 Sakai, a sequenced O157 outbreak 
strain from Japan. The Sakai PchA and Ler regulons were converted to EDL933 gene 
designations using the nucmer genomic alignment tool at coliBASE 
(http://xbase.bham.ac.uk/colibase/) and by BLAST analysis. Analysis of overlap between 
these regulons and genes affected by inhibitor treatment were performed in Genespring 
7.3.1.  
Determination of LEE expression using GFP reporter fusions  
Expression of the LEE was determined by using a series of plasmid-based promoter::GFP 
reporter fusions, described previously (pAJR71-75) (35). To measure population 
fluorescence, triplicate 100 µl aliquots of transformed bacteria were dispensed into 96-
well black microtitre plates and analysed using a BMG Fluostar plate reader at 37 °C.  
Cultures were also monitored at OD600 to monitor growth.  Fluorescence was plotted 
against optical density using Microsoft Excel software and the line of best fit obtained.  
The promoter-less plasmid, pAJR70 (35) was employed to correct for background 
fluorescence of the strain and media.  Comparisons between treated and culture treated 
with DMSO alone were determined at an OD600 of 0.8 to provide the best comparison 
with the data obtained by transcriptomics.  
Fluorescence microscopy analysis of LEE1 and flagella expression 
Embryonic bovine cells (German Collection of Microorganisms and Cell Cultures, no. 
ACC192) were prepared and cultured as described previously (32).  TUV-930 pAJR71 
(LEE1::GFP) was cultured in MEM-HEPES to OD600 0.6 at 37 °C with 20 μM ME0055 
or the same volume of DMSO.  Bacteria were added to the multi-chamber slide and 
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incubated at 37oC.  The samples were fixed at intervals by removal of the culture and 
addition of 4 % paraformaldehyde (PFA).  Detection of flagella expression was carried 
out as described previously (10).  The adherent bacteria were stained with rabbit anti-
O157 and anti-H7 polyclonal antiserum (Mast Diagnostics; diluted 1:500 in PBS) at RT 
for 30 min, washed then incubated with TRITC-labeled secondary antibody (Sigma anti-
rabbit; diluted 1:1000). Time points analyzed were 60, 120, 180 and 300 minutes after 
bacterial addition.  To measure single-cell expression by fluorescence microscopy, a Z-
stack of 20 images was captured at a spacing of 0.1 µm on a Zeiss Axioimager M1 
fluorescence microscope equipped with a Hamamatsu ORCA AG camera using Volocity 
software (Improvision).  These images were used to create a composite image that 
reduced the spatial effects of bacteria in different focal planes.  GFP intensity was 
determined using Volocity software with a threshold of 2000 relative fluorescence units 
as the cut-off point to separate GFP "positive" and GFP "negative" bacteria. 
Detection and quantification of A/E lesions  
To detect host cell actin, cells were permeabilized using 0.2% Triton X100 then treated 
for 20 min at RT with TRITC-Phalloidin (5µg.ml-1; Sigma) washed twice with PBS and 
mounted in fluorescent mounting medium (DAKO).  Improvision Volocity software 
(Quantification) was used to examine 3 independent replicates of the experiment and 
sampling 15 separate fields per replicate.  Bacteria and areas of concentrated actin were 
identified using size and fluorophore as selection parameters.  The percentage of total 
bacteria in each field associated with condensed actin was then determined. 
RESULTS 
Effects of salicylidene acylhydrazide inhibitors on growth rate. 
Our initial work aimed to determine the effects of the compounds on bacterial growth 
rate.  We were aware that marked changes in growth rate result in changes of global gene 
expression making any specific effects of the compounds hard to determine.  Bacteria 
were cultured in MEM-HEPES media containing a range (10 – 50 μM) of the four 
compounds.  At both 10 and 20 μM we observed only minor changes in growth rate 
8 
(Table 1) for all 4 compounds.  Addition of higher concentrations (50 μM) of the 
compounds had more marked effects on specific growth rate (Table 1).  We therefore 
focused our studies the 20 μM concentration to minimize any effects of altered growth 
rate on gene expression.  
Effect of salicylidene acylhydrazide inhibitors on secretion of T3SS effector proteins. 
In order to characterize the effects of the four inhibitors on the secretion of effector 
proteins by the T3SS, total secreted proteins were prepared from strain TUV-930 cultured 
in MEM-HEPES medium containing 20 μM of the inhibitor or the equivalent volume of 
DMSO. Secreted protein profiles were analysed by Colloidal blue staining of the total 
secreted proteins produced by the bacteria as well as Western blotting to quantify both 
the whole cell expression and secretion of the translocated intimin receptor (Tir) 
secretion. Addition of 20 μM of the compounds resulted in inhibition of Tir expression 
for all four compounds with ME0053 and ME0055 being the most effective, reducing Tir 
expression in the whole cell fraction by >90% (Figure 2). Analysis of the secreted 
fractions resulted in no detectable Tir when the bacteria were treated with ME0055, 
which correlates with the major reduction in whole cell expression by this compound. 
Treatment with ME0053 gave a reduced but detectable signal implying that, while whole 
cell expression of Tir was reduced, its secretion was not strongly inhibited.  ME0052 and 
ME0054 were less effective, reducing Tir expression by 39% and 54% respectively. 
ME0054 resulted in strong inhibition of Tir secretion whereas ME0052 did not appear to 
reduce secretion of Tir and the secreted fraction correlated closely to that of the whole 
cell fraction.  
The same samples were also tested for the translocator protein, EspD that is transcribed 
from a different operon within the LEE.  Addition of ME0054 or ME0055 gave strong 
inhibition of whole cell EspD expression (>95% reduction) and correspondingly low 
(ME0054) or undetectable (ME0055) levels of EspD in the supernatant fraction (Figure 
2).  ME0053 was less effective at blocking whole cell expression although the level of 
secreted EspD was markedly reduced.  ME0052 was the least effective inhibitor and both 
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whole cell expression and secreted levels showed similar reductions to those observed for 
Tir.   
These data were confirmed by Colloidal blue visualization of total secreted proteins 
which showed a concentration-dependent inhibitory effect on the overall secretion profile 
that varied between compounds with ME0055 being most effective, followed by 
ME0054, ME0053 and ME0052 (data not shown).  As a control, intracellular GroEL 
levels were also assessed by Western analysis (Figure 2).  These results showed that the 
compounds do not affect general protein expression or stability and less than 15% 
variation between the samples was observed.   
To examine if the observed inhibition of translocator and effector protein expression and 
secretion was due to the slight reduction of bacterial growth rate caused by addition of the 
compounds, we tested the relationship between growth rate and secretion phenotype.  To 
reduce bacterial growth rate independently of the salicylidene acylhydrazide inhibitors, 
NaCl was added to increase the osmolarity of the growth medium.  When compared to 
the bacteria cultured in MEM-HEPES alone, the addition of NaCl caused an increase in 
Tir protein secretion (Figure 2).   Additional of 0.1M NaCl reduced bacterial growth by 
18% (data not shown) and increased the level of secreted Tir by 34% (Figure 2).  
Addition of 0.2M NaCl reduced the growth rate by 44% leading to an increased level of 
Tir secretion by 61%.  These data suggest that the decrease in growth rate seen by 
addition of the salicylidene acylhydrazide inhibitors is unlikely to account for the 
inhibition of T3S. 
To examine if the compounds would act across a range of strains, six further E. coli O157 
isolates were tested against all four compounds (Table 2).    These consisted of three 
isolates from human outbreaks (ZAP 229, ZAP 231 and ZAP 243) and three isolates 
sourced from bovine samples (ZAP3, ZAP 11 and ZAP 12).  These strains cover 4 
different phage types (2, 4, 8, and 21/28), all commonly associated with disease outbreaks 
in the UK.  For these assays, any variation in the extent of the secretion inhibition was 
determined by blotting for secreted Tir (Table 2). Addition of ME0052, whilst largely 
ineffective in TUV-930, resulted in inhibition of Tir secretion in the additional 6 strains 
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(Table 2).  ME0053 showed inhibition against TUV-930 and the addtional 6 strains, but 
the extent of inhibition varied considerably.  ME0054 was the most effective inhibitor 
across the entire strain collection.  In comparison, ME0055 which was highly effective 
against 4 strains was far less inhibitory when tested against ZAP229, ZAP231 and 
ZAP243, reducing Tir secretion by only 43-60% (Table 2).   
Analysis of transcriptional changes resulting from inhibitor addition. 
In an effort to understand the molecular mechanism by which the inhibitory compounds 
function we carried out transcriptional profiling experiments.  Strain TUV-930 was 
grown to an OD600 of 0.8 in MEM-HEPES media in the presence or absence of 20 μM of 
inhibitor and RNA harvested and labeled for microarray analysis.  Table 3 shows 
cumulative results for genes with >2 fold change in all 4 inhibitor samples.  The data 
show that all 4 inhibitors reduce the expression of all LEE-encoded genes (Figure 3).  
Furthermore, in addition to repressing the LEE, all tested inhibitors also repress 
transcription of the non-LEE encoded effectors nleA, espJ, and espN, and pO157 ORFs 
L7027 and L7037.   The compounds predominantly repressed gene expression and they 
varied in the total number of genes affected.  For example, using a cut-off of a >3 fold 
change in transcription, ME0052 significantly (p ≤ 0.05) affected the transcription of 181 
genes whereas this was reduced to 24 genes for ME0055 (Tables 3, 4 & 1S).   
Repression of cryptic prophage encoded genes was observed across all inhibitors with 
52% (ME0052), 57% (ME0053), 78% (ME0054) and 19% (ME0055) of affected genes 
encoded on cryptic prophage (Table 4).  Genes with >2 fold or >3 fold change for each 
inhibitor were found to be significantly biased towards laterally acquired O-island (OI) 
encoded DNA (27) for  compounds ME0052, ME0053 and ME0054 using a Chi squared 
test (P<0.0001, Table 4).  ME0055 fell short of this level of significance, probably due to 
the small subset of genes affected by this compound.   
The finding that the transcriptional changes induced by salicylidene acylhydrazide 
compounds are biased towards a subset of OI-encoded genes suggested that a global 
regulator of horizontally-acquired DNA was being affected by the inhibitory compounds. 
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We therefore examined the array data to determine if any of the established regulators of 
the LEE and other horizontally-acquired genes was affected by the compounds.  17 
previously-characterised regulators (see (19) for an excellent review) were analysed to 
determine if the compounds resulted in transcriptional changes to their expression.  For 
several of these, the analysis was expanded to examine the genes known to be controlled 
by these regulators.  Figure 4 shows the effect of all four compounds on the regulators.  It 
is clear that the majority (hha, sdiA, recA, rpoS, qseA, fis, yhiF, yhiE, lexA and hns) show 
no marked changes in their transcription. To examine if compounds could be affecting 
the regulators post-transcriptionally, the regulons of H-NS, LexA and RecA were 
examined.   
The histone-like nucleoid structuring protein (H-NS) is a pleiotropic regulator of gene 
expression that plays an important role in transcriptional inactivation of horizontally 
acquired DNA (7, 23) . We used the E. coli K-12 H-NS regulon described by Oshima et 
al (26) to look for transcriptional changes within the E. coli K-12 “backbone” (genes that 
are common to both K-12 and O157) that would be indicative of changes in H-NS 
regulation.  Of the 63 genes affected by deletion of H-NS we found that 10 genes were 
significantly (p ≤ 0.05) up or down regulated at least two fold, however the majority of 
the regulon (53 genes) were unaffected by addition of inhibitor (Suppl. Figure 1SA & B).  
These data suggest that the compounds do not function by affecting global H-NS 
regulation.  
LexA and RecA mediate the SOS response to DNA damage in E. coli K-12. The SOS 
response is known to be a key regulator of lambdoid bacteriophage transcription as RecA 
stimulates auto-cleavage of the phage repressor, cI in response to DNA damage, 
triggering a cascade that leads to transcription of the Q antiterminator transcript and the 
lytic cycle.  LexA has also been shown to regulate the LEE in Enteropathogenic E. coli 
placing both the LEE and potentially phage regulated transcripts under the control of the 
SOS response (21).  However, transcripts within the LexA regulon were not significantly 
repressed in inhibitor treated cultures.  It therefore seems unlikely that inhibition of LexA 
de-repression is the mechanism of transcriptional silencing of T3SS (Suppl. Figure 1SC).   
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Whereas the majority of the regulators showed no changes in expression by addition of 
the compounds, the LEE-located regulators ler (encoding Ler), grlA and grlR all show 
consistent down-regulation upon treatment with all four inhibitors.  The finding that ler 
and grlA/R show co-ordinate down-regulation is consistent with previous reports (6) (12).  
The genes encoding pchA-C also showed some changes, particularly after addition of 
ME0055, the most potent inhibitor of Tir secretion.  The T3S regulators, Ler and PchA, 
have been shown to bind and positively activate transcription of a number of genes 
encoded on O-islands (1). Comparison of genes affected by inhibitor treatment and the 
Ler/PchA regulon defined by Abe and co-workers (2008, L1 and L2) indicates that 
significant overlap exists between these regulons (Supp. Table 1S).  Fifty two of 100 
genes repressed by ME0052, 39/60 repressed by ME0053, 11/21 repressed by ME0054, 
and 6/19 repressed by ME0055 are bound or regulated by Ler or PchA. PchA binds and 
positively regulates a number of secreted effectors encoded on horizontally acquired 
elements such as cryptic prophage. Supplementary Table 1S shows that a number of the 
non-LEE encoded effectors are repressed by inhibitor treatment indicating that in addition 
to repressing transcription of the T3SS machinery, translocated effectors encoded outside 
of the LEE are also down regulated.  
Iron starvation is proposed to play a key role in the virulence attenuating properties of 
these T3S inhibitors in Chlamydia pneumoniae (37).  Related compounds have been 
shown to sequester iron and addition of high concentrations (200 μM) of iron sulfate or 
iron chloride to inhibitor treated cultures is able to reverse the inhibitory effects of these 
compounds. Our own studies support this finding in that addition of 200 μM FeSO4 
reverses the effect of ME0053 in TUV-930 (data not shown).  In order to assess the 
effects of the inhibitors on iron availability within the cell, we used the RegulonDB 
database definition of the Fur regulon in E. coli K-12 (http://regulondb.ccg.unam.mx/) 
(8). Of 16 genes known to be Fur regulated none were significantly affected by addition 
of inhibitor (Suppl. Figure 1SD).  Similarly, using the GO ontology “iron transport” sub-
set of 29 genes (GO6826), no genes involved in iron transport were affected by all four 
inhibitors indicating intracellular iron supplies are not affected at the concentration of 
inhibitor used in this study (Suppl. Fig. 1S panel E).  It should be noted that the growth 
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media contained 250 nM Fe(NO3)2 which might mask any effects on iron availability.  
Finally, to confirm that the 20 μM concentration of inhibitor was not modulating gene 
expression by perturbing bacterial growth rate, we analysed both the rpoS (z4049) and 
groEL genes (z5748) and found them to be not significantly affected by addition of the 
four compounds (data not shown). 
Whilst the majority transcriptional change conserved across all four inhibitors were down 
regulated, pspDC and yjiY were significantly upregulated by inhibitor treatment (p≤0.05). 
pspBC is part of the phage shock protein response and analysis of the transcriptional data 
indicates that the rest of the operon encoding pspAB and pspE is induced albeit to a lesser 
degree. The phage shock protein response has previously been reported to be induced by 
loss of proton motive force, notably through the insertion of filamentous phage pIV 
secretin. It is also essential for membrane insertion of the YscC secretin of the Yersinia 
T3SS (5). yjiY was also consistently induced in inhibitor treated cultures however there 
has been little characterisation of this protein apart from its induction under conditions of 
stress such as growth in urine and pH stress (17, 38)  
Reporter gene analysis 
As an independent verification of the array data we used a series of GFP reporter fusions 
to analyze the effects of the compounds on the promoters of the LEE and the rpsM gene 
as a control.  Previous work has shown that the majority of LEE genes are transcribed by 
promoters that encompass 5 polycistronic operons named LEE1-5 (20).  We therefore 
used LEE1-5 plasmid-based GFP reporter fusions (35) to verify the transcriptomic data 
and show inhibition of LEE transcription. The same 20 μM concentration of each 
compound was used as in the transcriptional profiling to provide a direct comparison of 
these data.  Expression of LEE1-5 was repressed in the presence of the inhibitors, 
consistent with microarray results (Table 5).  The control fusion, consisting of the rpsM 
promoter which drives expression of the small ribosomal RNA protein, was unaffected by 
addition of the compounds consistent with the microarray findings (Table 4).  
Effect on A/E lesion formation 
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The Western analyses demonstrated that compound ME0055 was the most effective of 
the four compounds at reducing expression and, therefore, secretion of the key virulence-
associated effector protein, Tir.  However, all the data presented above consisted of in 
vitro assays, the majority of which used tissue culture media to stimulate expression of 
the LEE.  This raised the question of whether the compound would affect the ability of E. 
coli O157 to bind host cells and form A/E lesions.  Using a bovine epithelial cell line 
(EBL) we analysed the ability of TUV-930 to form A/E lesions.  Following a 6 hour 
infection period, we observed that the bacteria cultured in the presence of 20 μM 
ME0055 were still capable of condensing host cell actin and forming distinctive pedestals 
(Figure 5b).  However, it was evident that the proportion of bacteria forming A/E lesions 
was reduced compared to the culture treated with DMSO alone (Figure 5a).  In order to 
quantify any differences, we used Volocity Quantification (Improvision) to identify 
bacteria associated with areas of dense actin within the 3-D images.  This was achieved 
using size and fluorescence intensity thresholds to identify bacteria, condensed actin and 
then areas of clear co-localisation.  This automated approach allowed us to collate the 
data from some 15 individual fields collected across triplicate repeats of the experiment.  
These analyses indicated that after 6 hours, 28% (± 3%) of bacteria treated with ME0055 
were associated with A/E lesions (Figure 5b).  This was significantly less (P<0.001) than 
the culture treated with DMSO alone for which some 69% (± 16%) of bacteria formed 
A/E lesions (Figure 5a). 
Effect on LEE1 gene expression and flagellae production during contact with bovine 
epithelial cells  
The reduction in the ability of TUV-930 to form A/E lesions implied that addition of 
compound ME0055 resulted in suppression of LEE expression even during contact with 
host epithelial cells.  To examine this result further, we performed cell binding assays 
using TUV-930 transformed with a LEE1::GFP reporter plasmid (pAJR71) to allow 
measurement of the ler expression during contact with epithelial cells.  Additionally, our 
observation that the compounds affected grlA and grlR expression implied that flagella 
production may be increased as these regulators have been shown to cross-regulate the 
LEE and flagellae (12). Furthermore, recent work has shown that during the cell infection 
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process, E. coli O157 undergo a rapid temporal shift from the expression of H7 flagella to 
production of the T3SS (15).  We therefore questioned if the inhibitory compounds would 
affect this transition.  To test this, immuno-fluorescence antibody straining was used to 
examine any effects on the expression of H7 flagellae.  After addition of the bacteria to 
the EBL cell line, the expression of LEE1::GFP was determined at fixed time points by 
addition of 4% PFA.  Figure 6 shows that 60 minutes after addition of TUV-930 to the 
EBL cell line there was a significant difference in LEE1::GFP expression when ME0055 
treated cells are compared with the culture treated with DMSO alone.  Both the 
proportion of bacteria expressing GFP and the GFP intensity of bacteria which were GFP 
“positive” were measured to be significantly different.  Over the time course, GFP levels 
are seen to reduce in the bacteria treated with DMSO alone.  The ME0055 treated cells 
follow a similar pattern in that GFP levels fall throughout the time course but both the 
proportion of GFP positive bacteria and the GFP intensity of these bacteria were observed 
to be consistently reduced compared to the culture treated with DMSO alone.  Staining 
for H7 revealed that the addition of ME0055 led to an increase in flagellal expression 
compared to the bacteria treated with DMSO alone.  Over the time course, H7 expression 
increased from 20% of the population at 60 minutes to 40% at 120 minutes and was still 
high (30%) some 5 hours after addition of the bacteria to the eukaryotic cell line.  These 
data indicate that addition of ME0055 suppresses LEE1 expression, even during host cell 
contact and leads to an increase in H7 expression.  Clearly, both these observations 
correlate well with the reduction in A/E lesion formation. 
DISCUSSION  
The central role of T3SSs in the pathogenesis of many bacterial species provides the 
impetus to develop strategies to interfere with their function.  To this effect, ‘virulence 
blockers’ have been described that selectively target expression or function of T3SSs in a 
number of bacterial species including Y. pseudotuberculosis, S. Typhimurium, C. 
pneumoniae, and EPEC. There exists marked conservation of elements of the T3SS 
between EPEC and EHEC, yet the transcriptional control of these systems is varied with 
many regulators of T3S being encoded on horizontally acquired DNA in this 
polylysogenic pathogen (31, 41, 42).  The variation in T3S regulation observed between 
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isolates of EHEC O157 has also been suggested to play an important role in the 
epidemiology of this pathogen (16). As salicylidene acylhydrazide inhibitors of T3S 
repress transcription of the T3SS, detailed investigation of the effects of these compounds 
on EHEC O157 is warranted. In this study we attempted to address two questions: firstly, 
is the T3S inhibition demonstrated in other pathogens observed in EHEC O157 and is 
there serotype- and strain- specific variation in these responses. Secondly, are there 
conserved- and/or inhibitor-specific transcriptional responses that may help us to 
understand their mode of action? 
In agreement with these previous studies examining repression of bacterial T3SS, we 
observed that all four compounds were capable of inhibiting secretion of virulence 
proteins from E. coli O157:H7.  Addition of higher concentrations of the compounds had 
marked effects on growth rate and were not used in subsequent experiments.  At 20 μM 
inhibition of Tir and EspD was observed without major effects to GroEL levels or growth 
rate.  Further, relative transcription levels of rpoS (z4049) or groEL genes (z5748) were 
not found to be significantly (p ≤ 0.05) affected by addition of any of the 4 compounds.   
This indicated that the transcriptional changes observed could not be simply attributed to 
changes in bacterial growth rate.  
The repression of T3S in a diverse range of pathogens suggests that there exists a 
common, conserved target.  The most conserved region of the T3SS lies in the basal 
apparatus proteins and has recently been proposed to be the target of related inhibitors in 
Shigella flexneri (39). We note that the results presented in this study are not 
contradictory to our findings as these authors show that treatment with inhibitor decreases 
the amount of basal apparatus found in the membrane, suggesting that inhibition occurs at 
a very early stage of assembly and insertion, or at the level of transcription. We would 
anticipate that if these inhibitors bind proteins of the T3S complex, related strains with 
conserved basal apparatus proteins would likely all be affected by the compounds to a 
similar, if not the same extent.  In the present study we found significant variation in the 
level of inhibition of T3S between strains.  We propose that this reflects inhibition 
through a more variable route such as the repertoire of LEE-regulators in any one strain.  
Indeed we previously reported that the EHEC O157:H7 Sakai strain differed from EHEC 
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O26:H- strain 193 in the presence of the ETT2-encoded negative regulators of LEE 
z3720 and z3734 (42), and variability in expression of the pchABCX genes has recently 
been described (41). We therefore favor a model of inhibition involving transcriptional 
repression of T3S that would be consistent with the strain variation and the global 
transcriptional changes we observe.  
To examine the effect of the compounds on gene regulation we examined the 
transcriptional profile of cells treated with all four inhibitors. The results presented 
indicate that ME0052-55 represses transcription of the LEE and non-LEE encoded 
virulence factors.  Surprisingly, ME0052 which was the least effective compound at 
limiting Tir secretion, produced the greatest effect on global gene transcription.  
Conversely, ME0055 showed much better repression of protein secretion but more 
limited global repression of transcription. Perhaps critically, espA, encoding the T3 
translocation filament, was strongly repressed by ME0055 and may indicate that 
repression of the translocon can have a more significant overall effect on protein 
secretion. 
Related salicylidene acylhydrazide compounds have been shown to repress expression of 
T3SS in C. pneumoniae, a phenotype that can be reversed by addition of high 
concentrations of iron.  These findings are supported by our own results which show that 
addition of 200 μM FeSO4 is able to reverse the effect of compound ME0053 in TUV-
930.  In order to assess the effects of these compounds on iron availability within the cell, 
we analyzed the transcriptome for changes that would be indicative of iron starvation.  
The ferric uptake regulator (Fur) is a key regulator of iron uptake under conditions of iron 
starvation, repressing expression of iron uptake pathways and virulence determinants 
such as Shiga toxin under iron replete conditions.  We did not observe marked changes in 
the Fur regulon or in genes associated with iron transport in inhibitor treated cells (Supp. 
Figure 2D & 2E) indicating that they are not iron starved.   
Repressed transcripts were biased towards O-island encoded genes, particularly those 
encoded on cryptic prophage (Table 4), many of these encode secreted effectors of the 
T3SS.  One explanation for the bias towards repression of the OI genes would be that one 
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or more key regulators of horizontally-acquired genes are affected by the addition of the 
compounds.  On this basis we examined the expression of regulators known to play a role 
in co-ordinate expression of virulence genes including H-NS, LexA, Fur, PchA and Ler. 
There was little indication within the transcriptional data that H-NS or LexA regulons 
were significantly affected by inhibitor treatment (Figure 1SC). In contrast, PchA and Ler 
were significantly repressed by inhibitor treatment. 
Recent transcriptional profiling and chromatin immunoprecipitation experiments by Abe 
and co-workers (1) have shown that both Ler and PchA can globally regulate 
transcription of the LEE and a significant number of non-LEE encoded effectors.  For 
many of these recently identified effectors this is the first indication of a regulatory 
mechanism that co-ordinates transcription with the LEE.  Transcriptional profiling of 
inhibitor treated cells indicates that repression of transcription is not confined to the LEE 
but is extended to pathogenicity island encoded virulence determinants such as the non-
LEE encoded effectors, elements of the Type II secretion pathway, and haemolysins 
encoded on pO157.  Comparison of the Ler/PchA regulon with genes conserved across 
all four inhibitor treatments shows that 6 of the 12 non-LEE encoded genes repressed by 
all inhibitor treatments are bound or regulated by PchA and/or Ler, and 30/166 are 
significantly repressed by at least one inhibitor treatment. PchA homologues exist in 
many pathogenic and non-pathogenic bacteria including Yersinia (YpsIP31758_0776), 
Salmonella (NP_700416.1), Shigella (NP_599072.1), EPEC (PerC), UPEC 
(NP_754054.1 and NP_755073.1) and non-pathogenic E. coli (yfdN) (29) and may 
contribute to expression of horizontally acquired elements in these bacteria. Our results 
suggest that modulating the activity of the PchA regulon may contribute to the broad anti-
virulence effects of these inhibitors in EHEC and, potentially, in other pathogenic 
bacteria.  Clearly, inhibition of Pch function, through changes in its expression or activity 
would be one possible mechanism for how numerous OI-encoded genes are co-ordinately 
down-regulated by the addition of the compounds.  Simultaneous repression of a number 
of virulence determinants would contribute to the effectiveness of these inhibitors to limit 
colonization of cattle and disease in humans.   
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In conclusion we have shown that salicylidene acylhydrazide inhibitors selectively inhibit 
the transcription of the T3SS and other OI-encoded genes of E. coli O157.  Our data 
suggest that, in E. coli O157 these compounds act through regulators rather than directly 
at the level of the type three secretion system apparatus.  We have also shown inhibitor-, 
and strain-specific effects that should be taken into consideration when determining the 
mode of action and therapeutic potential of such molecules.  Our ongoing studies are 
using a combination of transposon mutagenesis screening and affinity purification to 
identify possible protein targets. 
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FIGURE LEGENDS 
 
FIG. 1: Structures of ME0052, ME0053, ME0054 and ME0055.  The compounds have been previously 
reported using a number of different nomenclatures: ME0052 (INP0010 & compound 8), ME0053 
(INP0403 & compound 11), ME0054 (INP0401 & compound 10) and ME0055 (INP0031 & compound 
17).   
 
FIG. 2: ME0052, ME0053, ME0054 and ME0055 inhibit expression and secretion of the effector proteins 
Tir and EspD, from E. coli O157:H7.  Secreted (S/N) and whole cell (W/C) fractions were prepared from 
bacteria cultured in MEM-HEPES.  Samples were separated by SDS-PAGE and analysed by Western 
blotting.  The antibodies used for the blots are indicated on the left.   To examine the effect of decreased 
growth rate on Tir secretion, E. coli O157:H7 was cultured in the absence (No addition: N/A) or presence 
of NaCl and secreted Tir detected by Western blotting.  The concentration of NaCl added is indicated.  
 
FIG. 3: A: Effect of all ME0052, ME0053, ME0054 and ME0055 on the transcription of the LEE. The fold 
change (log2) in transcription of treated versus culture treated with DMSO alone has been plotted for all the 
genes encoded on the LEE (OI-148A).  The strong repressive effect of the compounds on LEE operons 1-5 
can be contrasted to the Prophage 933L genes on the left hand side of the figure.  B: As a reference, a 
diagram of the LEE from strain EDL933 is presented showing the 5 polycistronic operons: LEE1-5.  The 
figure was produced from using Colibase (http://xbase.bham.ac.uk/colibase/). 
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FIG. 4: Effect of ME0052, ME0053, ME0054 and ME0055 on the transcription of known regulators of the 
LEE.  The fold change (log2) in transcription of treated versus cultures treated with DMSO alone has been 
plotted for 17 characterised regulators.   
 
FIG. 5: Addition of ME0055 affects formation of attaching and effacing lesions on bovine epithelial cells 
(EBLs).  Bacteria were cultured in the presence of DMSO (Fig. 5a) or 20 μM ME0055 (Fig. 5b) and added 
to the EBL cell line.  After 6 hours, the cells fixed using 4% paraformaldehyde and stained to show host 
cell actin (red, TRITC-phalloidin) and bacteria (green, α-O157 and Alexifluor 488 secondary conjugate).  
Composite, overlay images from 15 Z stack sections are presented. 
 
FIG. 6: Effect of ler gene expression during contact with bovine epithelial cells (EBLs) in the DMSO 
(panels A1-A4) or ME0055 (panels B1-B4) treated bacteria.  Bacteria transformed with the lee1::GFP 
reporter plasmid (pAJR71) were added to EBL cells, the samples fixed using 4% PFA, and visualised using 
α-O157/H7 antibodies and Alexifluor 555 secondary conjugates.  Time points analyzed were 60 (A1/B1), 
120 (A2/B2), 180 (A3/B3) and 300 (A4/B4) minutes after bacterial addition.  Composite, overlay images 
from 20, 0.1 μM Z stack sections are presented.  Panel C: quantification of lee1::GFP expression during 
bacterial contact with host cells.  Samples marked “-” and “+” contained DMSO or ME0055 respectively. 
Panel C1-C4 shows the quantified level of GFP per bacterial cell (relative fluorescence units) for the same 
time points as described in FIG. 6A and B.  The proportion of bacteria that showed GFP expression above a 
threshold level and the proportion of bacteria that were found to express flagellae are also shown (red bars). 
 
FIG. 1S: Analysis of H-NS, LexA and iron utilization/transport regulons of inhibitor treated cultures.  The 
fold change (log2) in transcription of treated versus cultures culture treated with DMSO alone has been 
plotted for the genes within each regulon: A&B, H-NS regulon presented on RegulonDB v6.2 
(regulondb.ccg.unam.mx/).  C, LexA regulon.  D, FUR regulon. E, GO “iron uptake” associated genes. 
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Figure 5
DMSO control
+20 μM ME0055
Figure 6
TABLE 1: Growth rates of strain TUV-930 ± inhibitors. 
 
 Compound 
(concentration) 
Specific growth  
rate  h-1  (mean ± 
SD) 
% growth 
inhibition 
None  0.54 ± 0.01 - 
ME0052 (10 μM) 0.49 ± 0.01 10 
ME0052 (20 μM) 0.44 ± 0.01 12 
ME0052 (50 μM) 0.37 ± 0.02 46 
ME0053 (10 μM) 0.49 ± 0.02 10 
ME0053 (20 μM) 0.44 ± 0.01 12 
ME0053 (50 μM) 0.06 ± 0.01 900 
ME0054 (10 μM) 0.54 ± 0.03 0 
ME0054 (20 μM) 0.50 ± 0.02 8 
ME0054 (50 μM) 0.49 ± 0.01 10 
ME0055 (10 μM) 0.54 ± 0.02 0 
ME0055 (20 μM) 0.50 ± 0.02 8 
ME0055 (50 μM) 0.44 ± 0.03 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2: Relative inhibition of T3S by salicylidene acylhydrazide compounds in 
different E. coli O157 strains.  The amount of secreted Tir effector protein was 
determined by Western analysis and compared to the strain when cultured in DMSO 
alone to determine the percentage inhibition.  “100” is therefore complete inhibition of 
Tir secretion.   
 
   Inhibitor 
Strain  Source Phage type ME0052 ME0053 ME0054 ME0055 
TUV-930 Human Not typed 23 68 98 99 
ZAP3 Bovine 2 100 100 100 100 
ZAP11 Bovine 21/28 100 100 100 100 
ZAP12 Bovine 21/28 100 100 100 100 
ZAP229 Human 2 80 59 97 60 
ZAP231 Human 4 79 75 95 43 
ZAP243 Human 8 86 94 91 44 
 
. 
  
 
TABLE 3.  Genes with >2 fold change in all inhibitor treatments and p<0.05 (Benjamini & Hochberg FDR) in 3 of 4 treatments. 
Transcription of rpsM and fliC have been included as controls. Genes upregulated by inhibitor treatment are shaded grey. 
ME0052 ME0053 ME0054 ME0055 Systematic 
name 
Common 
name OI#*  Effector** mobile element* 
Ler and 
PchA *** Ratio p-value  Ratio p-value Ratio p-value Ratio p-value 
L7027 L7027   pO157  0.361 3.08E-03 0.483 1.62E-01 0.328 5.89E-02 0.337 8.44E-02 
L7031 L7031   pO157 reg 0.141 1.27E-03 0.464 3.68E-02 0.151 1.05E-01 0.32 6.75E-02 
Z0955 Z0955 36  CP-933K P+L 0.083 2.13E-04 0.214 4.11E-02 0.096 9.60E-02 0.155 6.75E-02 
Z1823 Z1823 50  CP-933N P 0.277 3.70E-05 0.349 8.09E-02 0.298 4.37E-02 0.218 2.86E-05 
Z1824 Z1824 50 espN CP-933N P 0.147 5.33E-04 0.214 1.42E-03 0.17 7.79E-03 0.435 3.50E-04 
Z2478 pspD     3.648 6.53E-05 2.338 6.46E-02 2.45 1.03E-01 3.567 5.04E-03 
Z2479 pspC     3.9 5.05E-05 2.444 5.19E-02 2.512 9.44E-02 3.97 7.69E-03 
Z3071 Z3071 79 espJ CP-933U P+L 0.152 3.49E-04 0.236 9.20E-03 0.168 3.01E-03 0.478 2.45E-01 
Z3572 argT     0.494 1.35E-03 0.492 1.00E-01 0.387 1.48E-02 0.262 6.02E-03 
Z5100 espF 148 espF1 CP-933L L 0.126 8.48E-03 0.452 4.74E-04 0.145 1.70E-01 0.268 8.42E-02 
Z5102 Z5102 148  CP-933L L 0.062 4.34E-03 0.357 2.87E-05 0.103 1.92E-01 0.125 5.12E-02 
Z5103 escF 148  CP-933L L 0.044 1.85E-03 0.306 3.23E-05 0.087 1.54E-01 0.162 7.38E-02 
Z5104 Z5104 148  CP-933L L 0.045 1.80E-03 0.305 5.35E-04 0.085 1.48E-01 0.138 5.03E-02 
Z5105 espB 148 espB CP-933L L 0.037 1.01E-03 0.216 3.90E-02 0.071 1.16E-01 0.122 7.56E-02 
Z5106 espD 148  CP-933L L 0.033 3.62E-03 0.261 5.87E-02 0.072 1.17E-01 0.061 4.71E-02 
Z5107 espA 148  CP-933L L 0.045 3.04E-03 0.437 2.11E-01 0.074 1.23E-01 0.037 2.42E-02 
Z5108 sepL 148  CP-933L L 0.083 3.97E-05 0.252 1.21E-03 0.065 1.01E-01 0.238 5.33E-02 
Z5109 escD 148  CP-933L P+L 0.107 5.47E-04 0.435 3.59E-05 0.105 1.59E-01 0.237 3.92E-02 
Z5110 eae 148  CP-933L P+L 0.040 2.24E-03 0.211 4.34E-05 0.061 9.04E-02 0.132 3.86E-02 
Z5111 Z5111 148  CP-933L P+L 0.056 7.15E-03 0.329 1.64E-02 0.084 1.48E-01 0.081 3.12E-02 
Z5112 tir 148 tir CP-933L L 0.079 2.12E-03 0.344 1.40E-05 0.103 1.24E-01 0.156 5.16E-02 
Z5113 Z5113 148  CP-933L P+L 0.072 3.23E-04 0.287 1.06E-03 0.082 1.26E-01 0.155 3.80E-02 
Z5114 Z5114 148  CP-933L P+L 0.057 5.71E-03 0.312 1.13E-03 0.075 1.24E-01 0.191 3.64E-02 
Z5115 Z5115 148 espH CP-933L P+L 0.071 2.57E-04 0.235 2.21E-03 0.065 6.92E-02 0.224 6.52E-02 
Z5116 sepQ 148  CP-933L P+L 0.033 9.11E-03 0.156 3.88E-04 0.047 6.05E-02 0.204 1.28E-02 
Z5119 escN 148  CP-933L P+L 0.134 7.62E-03 0.388 1.47E-04 0.123 1.32E-01 0.333 1.32E-02 
Z5120 escV 148  CP-933L P+L 0.088 1.01E-02 0.285 5.95E-04 0.114 1.06E-01 0.398 1.91E-02 
Z5121 Z5121 148  CP-933L P+L 0.064 1.08E-02 0.273 2.96E-03 0.092 1.27E-01 0.328 8.38E-03 
Z5123 Z5123 148  CP-933L P+L 0.139 5.37E-03 0.361 1.69E-02 0.118 1.16E-01 0.176 3.22E-02 
Z5124 escJ 148  CP-933L P+L 0.081 4.69E-03 0.272 5.05E-04 0.111 7.00E-02 0.259 4.04E-02 
Z5125 Z5125 148  CP-933L P+L 0.047 1.05E-02 0.233 1.79E-02 0.085 1.01E-01 0.27 9.86E-03 
Z5126 escC 148  CP-933L P+L 0.112 6.86E-03 0.307 7.42E-03 0.087 1.04E-01 0.173 2.91E-02 
Z5127 cesD 148  CP-933L P+L 0.075 6.20E-03 0.237 2.02E-02 0.062 8.64E-02 0.178 1.73E-02 
Z5128 Z5128 148  CP-933L P+L 0.04 5.09E-03 0.177 5.26E-03 0.056 7.90E-02 0.179 5.51E-02 
Z5129 Z5129 148  CP-933L P+L 0.083 1.06E-03 0.244 8.03E-04 0.076 8.62E-02 0.204 2.14E-02 
Z5131 Z5131 148  CP-933L P+L 0.035 3.05E-03 0.256 1.10E-02 0.076 1.09E-01 0.397 3.56E-03 
Z5132 escU 148  CP-933L P+L 0.025 1.07E-02 0.14 4.94E-03 0.044 2.57E-02 0.463 7.15E-02 
Z5133 escT 148  CP-933L P+L 0.043 8.33E-07 0.178 1.54E-02 0.088 4.77E-02 0.3 1.82E-03 
Z5134 escS 148  CP-933L P+L 0.088 1.57E-03 0.18 1.67E-02 0.085 7.07E-02 0.374 4.24E-02 
Z5135 escR 148  CP-933L P+L 0.117 2.84E-04 0.179 2.74E-02 0.086 4.95E-02 0.304 4.41E-04 
Z5137 Z5137 148  CP-933L P+L 0.14 1.12E-02 0.216 2.29E-02 0.091 2.44E-02 0.148 1.09E-05 
Z5139 Z5139 148  CP-933L P+L 0.233 2.46E-03 0.295 4.66E-02 0.143 4.93E-03 0.173 3.92E-05 
Z5142 Z5142 148 espG CP-933L P+L 0.089 9.46E-04 0.221 1.72E-03 0.092 3.57E-02 0.298 7.90E-02 
Z5953 yjiY     12.27 2.22E-06 4.792 2.84E-03 4.997 2.60E-02 2.653 1.66E-01 
Z6024 Z6024 71 nleA CP-933P P+L 0.077 1.49E-03 0.196 3.13E-03 0.075 8.08E-02 0.38 6.11E-02 
Z4668 rpsM     0.673 0.015 0.926 0.159 1.103 0.219 0.965 0.585 
Z3013 fliC     4.305 0.061 33.830 0.020 5.064 0.111 0.311 0.340 
TABLE 4. Comparison of total number of genes with >2 fold change* in transcription 
for each inhibitor and number of genes encoded on O-islands and cryptic prophage 
(CP-933).  
 
 
Total # 
genes # OI encoded 
 
p** # CP-933 encoded 
 
p** 
ME0052 181 118 7.2e-32 94 1.3e-52 
ME0053 72 46 8.2e-13 41 1.5e-25 
ME0054 23 18 2.2e-08 18 1.2e-19 
ME0055 36 7 0.22 7 0.41 
Genome*** 5481 1449 0.98 727 0.98 
*>3 fold change was used as the threshold for inhibitors ME0052 and ME0054.   
**  p-values were calculated using a chi squared test with Yates correction. Expected 
values were generated from the total number of OI or CP-933 genes encoded within 
the genome as described by Perna et al (2001) and expressed as a relative proportion 
of the total # genes with 2 fold change. p values represent the significance of the bias 
toward OI or CP-933 encoded genes. 
***Total number of genes encoded by E. coli O157 EDL933 in each category. 
Annotation taken from Perna et al (2001). 
TABLE 5.  Analysis of promoter-GFP constructs cultured in MEM-HEPES in 
presence and absence of the small molecule inhibitors.  Ratio values are calculated 
from the fluorescence value of the strain cultured with the inhibitor divided by the 
strain cultured in the absence of the compound.  All values were corrected for 
background by deducting the fluorescence value for the strain transformed with 
pAJR70 (promoterless gfp) measured at the same optical density. 
 
ME0052 ME0053 ME0054 ME0055
Plasmid Promoter Ratio Ratio Ratio Ratio 
pAJR71 LEE1 0.23 0.25 0.25 0.38
pAJR72 LEE2 0.38 0.55 0.21 0.120
pAJR73 LEE3 0.21 0.41 0.16 0.328
pAJR74 LEE4 0.21 0.34 0.17 0.17
pAJR75 LEE5 0.19 0.45 0.19 0.25
pAJR145 rpsM 0.98 0.99 1.1 0.98
 
 
 
TABLE 1S: Genes with altered expression in inhibitor treated E. coli TUV93.0 
ME0052 >3 fold change p<0.05 B&H       
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
L7004 L7004   pO157  putative hemolysin expression modulating protein 0.183 0.00598 
L7024 L7024   pO157  regulatory protein 0.317 0.0074 
L7029 L7029   pO157  putative acyltransferase 0.31  0.00105 
L7031 L7031   pO157 reg hypothetical protein 0.141 0.00127 
L7032 etpC   pO157 reg type II secretion protein 0.173 0.000124 
L7033 etpD   pO157 reg type II secretion protein 0.247 7.02E-06 
L7036 etpG   pO157  type II secretion protein 0.25  5.50E-07 
L7038 etpI   pO157  type II secretion protein 0.323 0.000189 
L7047 hlyC   pO157  hemolysin transport protein 0.326 0.00128 
L7048 hlyA   pO157  hemolysin toxin protein 0.287 0.000169 
L7050 hlyD   pO157 reg hemolysin transport protein 0.104 0.000116 
L7094 L7094   pO157  transposase 0.228 0.00438 
Z0012 htgA     positive regulator for sigma 32 heat shock promoters 3.456 0.00356 
Z0016 gef     
Gef protein interferes with membrane function when in 
excess 0.222 0.000294 
Z0086 leuO     probable transcriptional activator for leuABCD operon 0.26  7.54E-05 
Z0157 sfsA     probable regulator for maltose metabolism 0.303 0.000306 
Z0367 Z0367 10  IS  unknown protein encoded in ISEc8 3.712 0.00393 
Z0371 Z0371 11    putative LysR-like transcriptional regulator 0.316 0.00986 
Z0395 Z0395 14   P+L  0.237 0.00623 
Z0415 Z0415 17    
putative periplasmic binding protein, probable substrate 
ribose 4.337 0.00954 
Z0461 Z0461 20    putative permease; hexosephosphate transport 3.332 0.000333 
Z0757 citG     orf, hypothetical protein 3.127 0.00307 
Z0878 sdhB     succinate dehydrogenase, iron sulfur protein 0.273 0.00187 
Z0893 Z0893 35    putative glutamate mutase subumit E 3.036 0.00211 
Z0919 nadA     quinolinate synthetase, A protein 5.096 3.48E-06 
Z0920 pnuC     required for NMN transport 4.4 0.00105 
Z0950 Z0950 36  CP-933K  unknown protein encoded by prophage CP-933K 3.239 0.00529 
Z0955 Z0955 36  CP-933K P+L unknown protein encoded by prophage CP-933K 0.083 0.000213 
Z0964 Z0964 36  CP-933K  putative DNA packaging protein of prophage CP-933K 3.032 0.00273 
Z0978 Z0978 36  CP-933K  putative tail component of prophage CP-933K 3.411 0.00535 
Z0985 Z0985 36 nleB-2 CP-933K P+L unknown protein encoded by prophage CP-933K 0.31  0.00635 
Z1047 ybiY     putative pyruvate formate-lyase 2 activating enzyme 3.112 0.000369 
Z1122 Z1122 43     3.011 0.00206 
Z1131 Z1131 43    unknown protein encoded in ISEc8 4.417 0.00268 
ME0052 cont.        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z1223 Z1223 43     3.242 0.00104 
Z1246 pflA     pyruvate formate lyase activating enzyme 1 0.329 0.00051 
Z1350 Z1350 44  CP-933M  putative holin protein of cryptic prophage CP-933M 3.128 0.0109 
Z1362 Z1362 44  CP-933M  unknown protein encoded by cryptic prophage CP-933M 4.422 0.00329 
Z1366 Z1366 44  CP-933M  unknown protein encoded by cryptic prophage CP-933M 4.082 0.00903 
Z1372 Z1372 44  CP-933M  unknown protein encoded by cryptic prophage CP-933M 3.821 1.00E-05 
Z1375 Z1375 44  CP-933M  
tail component encoded by cryptic prophage CP-933M; 
partial 3.559 0.00931 
Z1377 Z1377 44  CP-933M  
putative tail component encoded by cryptic prophage CP-
933M 5.397 0.00208 
Z1378 Z1378 44  CP-933M  
tail component encoded by cryptic prophage CP-933M; 
partial 3.134 0.000326 
Z1382 Z1382  44  CP-933M  
tail component encoded by cryptic prophage CP-933M; 
partial 3.083 0.00145 
Z1468 Z1468 45  BP-933W  putative lysis protein S of bacteriophage BP-933W 5.177 3.42E-06 
Z1471 Z1471 45  BP-933W  
putative antirepressor protein Ant of bacteriophage BP-
933W 4.361 0.00341 
Z1526 ycdS     putative outer membrane protein 0.297 0.00689 
Z1527 ycdT     orf, hypothetical protein 0.163 0.0107 
Z1538 Z1538 47    putative pilin subunit 0.287 0.009 
Z1576 Z1576 48     4.271 0.000537 
Z1765 xisN 50  CP-933N  putative excisionase for prophage CP-933N 0.131 0.000278 
Z1771 ydaS 50  CP-933N  unknown protein encoded by prophage CP-933N 0.16  0.00027 
Z1774 Z1774 50  CP-933N  unknown protein encoded by prophage CP-933N 0.33  0.00367 
Z1778 Z1778 50  CP-933N  unknown protein encoded by prophage CP-933N 0.3 8.15E-05 
Z1779 Z1779 50  CP-933N  unknown protein encoded by prophage CP-933N 0.279 3.68E-05 
Z1798 Z1798 50  CP-933N  putative endopeptidase of prophage CP-933N 3.301 0.0086 
Z1807 Z1807 50  CP-933N  unknown protein encoded by prophage CP-933N 5.282 0.000793 
Z1814 Z1814 50  CP-933N  unknown protein encoded by prophage CP-933N 3.429 0.00275 
Z1822 Z1822 50 espX7 CP-933N P unknown protein encoded by prophage CP-933N 0.095 2.80E-05 
Z1823 Z1823 50  CP-933N P unknown protein encoded by prophage CP-933N 0.277 3.70E-05 
Z1824 Z1824 50 espN CP-933N P unknown protein encoded by prophage CP-933N 0.147 0.000533 
Z1901 Z1901 52  CP-933X  unknown protein encoded by prophage CP-933X 4.966 0.00767 
Z1912 Z1912 52  CP-933X  unknown protein encoded by prophage CP-933X 3.184 0.00116 
Z1924 Z1924 52  CP-933X  unknown protein encoded by prophage CP-933X 8.707 0.000286 
Z1928 Z1928 52  CP-933X  unknown protein encoded by ISEc8 in prophage CP-933X 5.1 0.00758 
Z1985 ychA     orf, hypothetical protein 0.253 0.00262 
Z2008 purU     formyltetrahydrofolate deformylase 0.263 0.0071 
 
 
 
ME0052 cont.        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z2130 Z2130 57  CP-933O  
putative IS encoded protein encoded within prophage CP-
933O 3.371 1.84E-05 
Z2170 marA     multiple antibiotic resistance; transcriptional activator 4.2 0.000298 
Z2339 Z2339 
hypervari
able  nleG2-2 CP-933R P unknown protein encoded by prophage CP-933R 0.211 0.00375 
Z2361 Z2361 
hypervari
able   CP-933R  putative capsid assembly protein of prophage CP-933R 5.304 1.49E-05 
Z2372 Z2372 
hypervari
able   CP-933R  unknown protein encoded within prophage CP-933R 5.653 0.000141 
Z2389 Z2389 
hypervari
able   CP-933R  
DNA modification methyltransferase within prophage CP-
933R 0.292 0.000419 
Z2414 ydaQ 
hypervari
able   CP-933R  unknown protein encoded within prophage CP-933R 4.269 9.95E-05 
Z2478 pspD     phage shock protein 3.648 6.53E-05 
Z2479 pspC     
phage shock protein: activates phage shock-protein 
expression 3.9 5.05E-05 
Z2480 pspB     phage shock protein, putative inner membrane protein 4.701 0.00518 
Z2482 pspA     phage shock protein, putative inner membrane protein 3.197 0.000673 
Z2744 pheM     
phenylalanyl-tRNA synthetase (pheST) operon leader 
peptide 0.26  0.00468 
Z2841 yeaS     orf, hypothetical protein 0.213 0.00272 
Z2866 yebH     putative enzyme 0.302 0.00766 
Z2879 Z2879     orf, hypothetical protein 0.27  0.00135 
Z2943 motB     enables flagellar motor rotation 3.186 0.000705 
Z2967 Z2967 76  CP-933T  unknown protein encoded by prophage CP-933T 0.278 0.000205 
Z2970 coxT 76  CP-933T  putative regulator for prophage CP-933T 0.167 4.17E-05 
Z2971 Z2971 76  CP-933T  unknown protein encoded by prophage CP-933T 0.156 1.17E-06 
Z2972 Z2972 76  CP-933T  unknown protein encoded by prophage CP-933T 0.137 0.00928 
Z2973 Z2973 76  CP-933T  unknown protein encoded by prophage CP-933T 0.204 8.34E-05 
Z3071 Z3071 79 espJ CP-933U P+L unknown protein encoded within prophage CP-933U 0.152 0.000349 
Z3082 Z3082 79  CP-933U  putative tail fiber component L of prophage CP-933U 3.604 0.00286 
Z3106 Z3106 79  CP-933U  putative holin protein of prophage CP-933U 3.885 0.000573 
Z3154 Z3154 81  IS  unknown protein encoded by ISEc8 4.937 0.00205 
Z3190 ugd     UDP-glucose 6-dehydrogenase 4.535 0.0105 
Z3202 wbdO 84    glycosyl transferase 0.293 0.00315 
Z3208 wcaL     putative colanic acid biosynthesis glycosyl transferase 4.373 0.00146 
Z3213 cpsB     mannose-1-phosphate guanyltransferase 4.578 0.00741 
Z3216 wcaG     putative nucleotide di-P-sugar epimerase or dehydratase 3.924 0.000397 
Z3217 gmd     GDP-D-mannose dehydratase 6.292 0.000967 
Z3219 wcaE     putative colanic acid biosynthesis glycosyl transferase 4.791 0.006 
Z3223 wcaA     putative regulator 3.457 0.00771 
 
 
 
ME0052 cont.        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z3251 Z3251     orf, hypothetical protein 0.28  0.0108 
Z3314 Z3314 93  CP-933V  putative tail component of prophage CP-933V 4.181 0.000641 
Z3319 Z3319 93  CP-933V  unknown protein encoded within prophage CP-933V 4.695 0.00033 
Z3320 Z3320 93  CP-933V  unknown protein encoded within prophage CP-933V 3.644 0.00313 
Z3326 Z3326 93  CP-933V  unknown protein encoded within prophage CP-933V 4.217 0.00837 
Z3331 Z3331 93  CP-933V  unknown protein encoded within prophage CP-933V 3.683 0.000556 
Z3332 Z3332 93  CP-933V  unknown protein encoded within prophage CP-933V 3.574 0.000295 
Z3333 Z3333 93  CP-933V  unknown protein encoded within prophage CP-933V 3.691 0.0107 
Z3770 Z3770     putative membrane protein 0.306 0.00527 
Z3856 nadB     quinolinate synthetase, B protein 4.356 2.09E-05 
Z3921 Z3921 108 nleG6-3' CP-933Y reg  0.305 0.00104 
Z3931 Z3931 108  CP-933Y P unknown protein encoded by prophage CP-933Y 0.299 0.000618 
Z4085 ygcW     putative oxidoreductase 4.326 0.00906 
Z4118 fucP     fucose permease 3.36  0.00898 
Z4119 fucI     L-fucose isomerase 3.078 0.000533 
Z4326 Z4326 122 espL2 IS P putative enterotoxin 0.276 0.000501 
Z4328 Z4328 122 nleB1 IS P  0.171 0.000348 
Z4329 Z4329 122 nleE IS P  0.157 0.00385 
Z4330 Z4330 122  IS  putative transposase 0.216 0.0035 
Z4331 Z4331 122  IS   0.321 0.000919 
Z4332 Z4332 122  IS  putative cytotoxin 0.101 0.000891 
Z4493 agaC     
PTS system N-acetylgalactosamine-specific IIC component 
1 3.793 0.00935 
Z4937 yhjG     orf, hypothetical protein 3.136 0.00108 
Z4939 yhjH     orf, hypothetical protein 3.348 0.00132 
Z4988 yiaB     orf, hypothetical protein 3.34  0.0106 
Z5051 waaJ 145    putative LPS biosynthesis enzyme 0.269 0.000337 
Z5052 waaY 145    putative LPS biosynthesis protein 0.319 0.000978 
Z5053 waaI 145    putative LPS biosynthesis enzyme 0.319 4.82E-05 
Z5098 Z5098 148  CP-933L  
unknown protein encoded by ISEc8 within prophage CP-
933L 3.736 0.003 
Z5100 espF 148 espF1 CP-933L  espF 0.126 0.00848 
Z5102 Z5102 148  CP-933L L  0.062 0.00434 
Z5103 escF 148  CP-933L L escF 0.044 0.00185 
Z5104 Z5104 148  CP-933L L  0.045 0.0018 
Z5105 espB 148 espB CP-933L L secreted protein EspB 0.037 0.00101 
Z5106 espD 148  CP-933L L secreted protein EspD 0.033 0.00362 
ME0052 cont.        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z5107 espA 148  CP-933L L secreted protein EspA 0.045 0.00304 
Z5108 sepL 148  CP-933L L sepL 0.083 3.97E-05 
Z5109 escD 148  CP-933L P+L escD 0.107 0.000547 
Z5110 eae 148  CP-933L P+L intimin adherence protein 0.040 0.00224 
Z5111 Z5111 148  CP-933L P+L  0.056 0.00715 
Z5112 tir 148 tir CP-933L L putative translocated intimin receptor protein 0.079 0.00212 
Z5113 Z5113 148  CP-933L P+L  0.072 0.000323 
Z5114 Z5114 148  CP-933L P+L  0.057 0.00571 
Z5115 Z5115 148 espH CP-933L P+L  0.071 0.000257 
Z5116 sepQ 148  CP-933L P+L sepQ 0.033 0.00911 
Z5117 Z5117 148  CP-933L P+L  0.133 0.00148 
Z5118 Z5118 148  CP-933L P+L  0.078 0.00856 
Z5119 escN 148  CP-933L P+L escN 0.134 0.00762 
Z5120 escV 148  CP-933L P+L escV 0.088 0.0101 
Z5121 Z5121 148  CP-933L P+L  0.064 0.0108 
Z5123 Z5123 148  CP-933L P+L  0.139 0.00537 
Z5124 escJ 148  CP-933L P+L escJ 0.081 0.00469 
Z5125 Z5125 148  CP-933L P+L  0.047 0.0105 
Z5126 escC 148  CP-933L P+L escC 0.112 0.00686 
Z5127 cesD 148  CP-933L P+L cesD 0.075 0.0062 
Z5128 Z5128 148  CP-933L P+L  0.04  0.00509 
Z5129 Z5129 148  CP-933L P+L  0.083 0.00106 
Z5131 Z5131 148  CP-933L P+L  0.035 0.00305 
Z5132 escU 148  CP-933L P+L escU 0.025 0.0107 
Z5133 escT 148  CP-933L P+L escT 0.043 8.33E-07 
Z5134 escS 148  CP-933L P+L escS 0.088 0.00157 
Z5135 escR 148  CP-933L P+L escR 0.117 0.000284 
Z5139 Z5139 148  CP-933L P+L  0.233 0.00246 
Z5142 Z5142 148 espG CP-933L P+L  0.089 0.000946 
Z5143 Z5143 148  CP-933L   0.106 6.79E-05 
Z5245 asnA     asparagine synthetase A 4.712 5.53E-07 
Z5367 fadB     4-enzyme protein: 3-hydroxyacyl-CoA dehydrogenase 0.234 0.00123 
Z5401 Z5401      4.126 0.00109 
Z5449 rhaS     positive regulator for rhaBAD operon 3.21  0.000746 
Z5503 yijI     orf, hypothetical protein 3.624 0.000757 
 
ME0052 cont.        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z5506 frwB     PTS system fructose-like IIB component 1 3.092 0.00023 
Z5615 Z5615 166    putative sorbose PTS component 3.007 0.00138 
Z5624 yjbE     orf, hypothetical protein 20.24 0.00277 
Z5675 nrfG     part of formate-dependent nitrite reductase complex 3.666 0.000125 
Z5690 Z5690 167    putative permease of ribose ABC transport system 3.172 0.00848 
Z5694 Z5694      3.209 3.21E-05 
Z5730 yjdK     orf, hypothetical protein 0.177 0.00642 
Z5953 yjiY     putative carbon starvation protein 12.27 2.22E-06 
Z6024 Z6024 71 nleA CP-933P P+L unknown protein encoded by cryptic prophage CP-933P 0.077 0.00149 
Z6033 Z6033 71  CP-933P  putative tail component of cryptic prophage CP-933P 3.941 0.0107 
Z6035 Z6035 71  CP-933P  putative tail assembly protein of cryptic prophage CP-933P 3.355 5.27E-06 
Z6046 Z6046 71  CP-933P  putative terminase encoded by cryptic prophage CP-933P 3.003 0.01 
         
ME0053 >2 fold change p<0.05 B&H        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
L7003 L7003   pO157  
hypothetical protein 15.6 kDa protein in finO 3' region 
precursor 0.363 4.03E-05 
L7004 L7004   pO157  putative hemolysin expression modulating protein 0.455 6.22E-05 
L7005 L7005   pO157  hypothetical protein 0.472 1.03E-05 
L7024 L7024   pO157  regulatory protein 0.371 9.27E-05 
L7025 L7025   pO157   0.437 6.07E-05 
L7030 L7030   pO157   0.395 0.00071 
L7032 etpC   pO157 reg type II secretion protein 0.425 3.31E-06 
L7033 etpD   pO157 reg type II secretion protein 0.385 0.00162 
L7050 hlyD   pO157 reg hemolysin transport protein 0.414 0.00162 
L7051 L7051   pO157  hypothetical protein 0.486 0.000645 
Z0394 Z0394 14    P+L  0.47  0.000406 
Z0395 Z0395 14   P+L  0.413 3.82E-05 
Z0701 Z0701 30     0.484 0.000234 
Z0728 fepE     ferric enterobactin (enterochelin) transport 0.486 0.000189 
Z0840 Z0840 32     0.427 0.000549 
Z0920 pnuC     required for NMN transport 3.555 0.000547 
Z0989 Z0989 36 nleH1-1 CP-933K P+L unknown protein encoded by prophage CP-933K 0.347 0.000179 
Z1012 ybhR     orf, hypothetical protein 2.225 0.00185 
Z1386 Z1386 44  CP-933M  unknown protein encoded by cryptic prophage CP-933M 0.461 6.01E-05 
ME0053 cont.       
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z1678 Z1678     orf, hypothetical protein 2.867 0.000267 
Z1824 Z1824 50 espN CP-933N P unknown protein encoded by prophage CP-933N 0.221 2.39E-05 
Z1829 Z1829 50  CP-933N P  0.484 0.000209 
Z1925 Z1925 52  CP-933X  unknown protein encoded by prophage CP-933X 0.238 2.98E-06 
Z2075 Z2075 57  CP-933O  unknown protein encoded by prophage CP-933O 0.38  8.97E-06 
Z2149 Z2149 57 nleG2-3 CP-933O P  0.366 0.000422 
Z2150 Z2150 57 nleG6-2 CP-933O   0.317 2.54E-06 
Z2184 uxaB     altronate oxidoreductase 2.26  0.00191 
Z2189 Z2189     putative LACI-type transcriptional regulator 2.355 0.000139 
Z2338 Z2338 
hyper
varia
ble nleG6-1 CP-933R P unknown protein encoded by prophage CP-933R 0.359 0.000276 
Z2339 Z2339 
hyper
varia
ble nleG2-2 CP-933R P unknown protein encoded by prophage CP-933R 0.234 0.000261 
Z2914 yebB      0.491 0.00136 
Z3071 Z3071 79 espJ CP-933U P+L unknown protein encoded within prophage CP-933U 0.24  0.00156 
Z3202 wbdO 84    glycosyl transferase 0.443 0.000895 
Z3593 yfcB     putative adenine-specific methylase 0.179 0.000907 
Z3921 Z3921 108 nleG6-3' CP-933Y reg  0.242 0.000232 
Z4771 malQ     4-alpha-glucanotransferase (amylomaltase) 2.118 0.000686 
Z4996 malS     alpha-amylase 2.252 0.00027 
Z5100 espF 148 espF1 CP-933L  espF 0.453 0.000123 
Z5102 Z5102 148  CP-933L L  0.357 4.40E-06 
Z5103 escF 148  CP-933L L escF 0.307 7.23E-06 
Z5104 Z5104 148  CP-933L L  0.308 9.49E-06 
Z5108 sepL 148  CP-933L L sepL 0.252 0.000119 
Z5109 escD 148  CP-933L P+L escD 0.437 4.33E-06 
Z5110 eae 148  CP-933L P+L intimin adherence protein 0.213 1.01E-06 
Z5112 tir 148 tir CP-933L L putative translocated intimin receptor protein 0.345 1.28E-06 
Z5113 Z5113 148  CP-933L P+L  0.288 0.000125 
Z5114 Z5114 148  CP-933L P+L  0.313 0.000148 
Z5115 Z5115 148 espH CP-933L P+L  0.238 0.000173 
Z5116 sepQ 148  CP-933L P+L sepQ 0.159 4.09E-07 
Z5117 Z5117 148  CP-933L P+L  0.232 0.000489 
Z5118 Z5118 148  CP-933L P+L  0.238 7.61E-05 
Z5119 escN 148  CP-933L P+L escN 0.391 4.29E-05 
Z5120 escV 148  CP-933L P+L escV 0.285 8.34E-05 
Z5121 Z5121 148  CP-933L P+L  0.275 0.00049 
ME0053 cont.       
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z5124 escJ 148  CP-933L P+L escJ 0.275 5.79E-06 
Z5126 escC 148  CP-933L P+L escC 0.316 0.000229 
Z5127 cesD 148  CP-933L P+L cesD 0.25  0.00167 
Z5128 Z5128 148  CP-933L P+L  0.182 0.000255 
Z5129 Z5129 148  CP-933L P+L  0.248 6.15E-06 
Z5131 Z5131 148  CP-933L P+L  0.263 0.00178 
Z5132 escU 148  CP-933L P+L escU 0.143 0.000275 
Z5133 escT 148  CP-933L P+L escT 0.188 0.0012 
Z5134 escS 148  CP-933L P+L escS 0.191 0.00105 
Z5142 Z5142 148 espG CP-933L P+L  0.224 0.000256 
Z5143 Z5143 148  CP-933L   0.117 0.000877 
Z5631 malF     part of maltose permease, periplasmic 3.805 0.000167 
Z5632 malE     periplasmic maltose-binding protein 3.282 0.000148 
Z5634 lamB    reg 
phage lambda receptor protein; maltose high-affinity 
receptor 5.17  0.000558 
Z5635 malM     periplasmic protein of mal regulon 4.756 0.000564 
Z5727 yjdH     putative 2-component sensor protein 0.479 0.000279 
Z5957 yjjM      2.174 0.000419 
Z6024 Z6024 71 nleA CP-933P P+L unknown protein encoded by cryptic prophage CP-933P 0.199 0.00047 
         
ME0054 >3 fold change p<0.1 B&H        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
L7030 L7030   pO157   0.32  0.00749 
Z0086 leuO     probable transcriptional activator for leuABCD operon 0.228 0.00153 
Z0394 Z0394 14   P+L  0.238 0.00692 
Z0985 Z0985 36 nleB-2 CP-933K P+L unknown protein encoded by prophage CP-933K 0.255 0.000895 
Z0989 Z0989 36 nleH1-1 CP-933K P+L unknown protein encoded by prophage CP-933K 0.317 0.00701 
Z1765 xisN 50  CP-933N  putative excisionase for prophage CP-933N 0.148 5.73E-05 
Z1766 Z1766 50  CP-933N  unknown protein encoded by prophage CP-933N 0.299 6.69E-05 
Z1774 Z1774 50  CP-933N  unknown protein encoded by prophage CP-933N 0.258 6.54E-05 
Z1775 Z1775 50  CP-933N  unknown protein encoded by prophage CP-933N 0.279 0.00123 
Z1776 Z1776 50  CP-933N  unknown protein encoded by prophage CP-933N 0.26  0.000571 
Z1777 Z1777 50  CP-933N  unknown protein encoded by prophage CP-933N 0.263 0.00102 
Z1822 Z1822 50 espX7 CP-933N P unknown protein encoded by prophage CP-933N 0.267 0.00187 
Z1824 Z1824 50 espN CP-933N P unknown protein encoded by prophage CP-933N 0.17  0.00779 
ME0054 cont.       
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z2149 Z2149 57 nleG2-3 CP-933O P  0.283 0.00619 
Z2150 Z2150 57 nleG6-2 CP-933O   0.292 0.00189 
Z2339 Z2339  nleG2-2 CP-933R P unknown protein encoded by prophage CP-933R 0.241 0.00224 
Z2909 yebL     putative adhesin 15.79 0.00811 
Z2910 yebM     putative ATP-binding component of a transport system 9.666 1.37E-05 
Z3066 Z3066      62.22 0.00737 
Z3071 Z3071 79 espJ CP-933U P+L unknown protein encoded within prophage CP-933U 0.168 0.00301 
Z3921 Z3921 108 nleG6-3' CP-933Y reg  0.178 0.00978 
Z5138 Z5138 148  CP-933L P+L  0.080 0.00756 
Z5139 Z5139 148  CP-933L P+L  0.143 0.00493 
Z5140 ler 148  CP-933L   0.138 0.00493 
         
ME0055 >2 fold change p<0.05 B&H        
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z0002 thrA     aspartokinase I, homoserine dehydrogenase I 0.424 5.52E-05 
Z0003 thrB     homoserine kinase 0.458 0.000383 
Z0004 thrC     threonine synthase 0.463 0.000149 
Z0232 yafD     orf, hypothetical protein 2.054 0.0148 
Z0900 cydA     cytochrome d terminal oxidase, polypeptide subunit I 2.155 2.42E-06 
Z0923 Z0923     putative homeobox protein 3.04  0.0345 
Z1248 pflB     formate acetyltransferase 1 2.438 0.0095 
Z1748 ndh     respiratory NADH dehydrogenase 3.661 0.0987 
Z1823 Z1823 50  CP-933N P unknown protein encoded by prophage CP-933N 0.219 2.52E-06 
Z1824 Z1824 50 espN CP-933N P unknown protein encoded by prophage CP-933N 0.402 0.00206 
Z2224 Z2224     putative transport system permease protein 0.285 0.000125 
Z2225 Z2225     putative transport protein 0.361 0.00158 
Z2227 Z2227     putative ATP-binding component of a transport system 0.332 2.13E-05 
Z2425 ydaJ     putative aminohydrolase (EC 3.5.1.14) 0.357 0.000325 
Z2477 pspE     phage shock protein 2.5 0.00463 
Z2478 pspD     phage shock protein 3.718 0.0209 
Z2479 pspC     
phage shock protein: activates phage shock-protein 
expression 4.096 0.039 
Z2480 pspB     phage shock protein, putative inner membrane protein 3.956 0.0479 
Z2482 pspA     phage shock protein, putative inner membrane protein 4.751 0.0529 
Z2548 trpD     anthranilate synthase component II 0.328 8.04E-05 
ME0055 cont.       
Systematic name  
Common 
name OI# effector  mobile element Ler/PchA* Product normalised p-value 
Z2646 ydgR     putative transport protein 2.472 0.000956 
Z2707 ynhA     orf, hypothetical protein 2.103 0.0337 
Z2711 ynhE     orf, hypothetical protein 2.562 0.0388 
Z2712 ydiC     orf, hypothetical protein 3.152 0.00648 
Z3147 nac     nitrogen assimilation control protein 0.481 1.99E-06 
Z3549 lrhA     NADH dehydrogenase transcriptional regulator, LysR family 2.134 0.00351 
Z3558 ackA     acetate kinase 2.195 0.0318 
Z3572 argT     lysine-, arginine-, ornithine-binding periplasmic protein 0.266 0.00094 
Z4631 yhdY     putative transport system permease protein 0.357 0.00182 
Z5131 Z5131 148  CP-933L P+L  0.356 4.59E-05 
Z5133 escT 148  CP-933L P+L escT 0.292 0.000935 
Z5137 Z5137 148  CP-933L P+L  0.151 4.41E-07 
Z5138 Z5138 148  CP-933L P+L  0.302 0.00249 
Z5139 Z5139 148  CP-933L   0.175 2.09E-06 
Z5678 fdhF     formate dehydrogenase 0.391 0.00145 
Z5855 pyrI     aspartate carbamoyltransferase, regulatory subunit 3.161 0.000152 
Z5856 pyrB     aspartate carbamoyltransferase, catalytic subunit 3.462 0.0549 
